What is the long-term trend for Relmada Therapeutics, Inc.'s operating loss carryforwards?

Over 2 years (2023 to 2025), Relmada Therapeutics, Inc.'s operating loss carryforwards has grown at a -66.1% compound annual growth rate (CAGR), from $41.56M to $4.77M.

Relmada Therapeutics, Inc. RLMD Operating Loss Carryforwards

Operating Loss Carryforwards at other companies

Hippo HoldingsHIPO

$663.9M—

KopinKOPN

$136.4M+22.3%

Hippo HoldingsHIPO

$543.8M—

PepsiCoPEP

$35.5B+4.4%

MSCIMSCI

$29.8M+4.9%

FIP

FTAI Infrastructure Inc.FIP

$1B+48.1%

Other financials

Income statement

See full

Operating income-$19.5M-6.8%

Net income-$19.1M-8.5%

EPS (diluted)-$0.22+62.1%

Balance sheet

See full

Cash & equivalents$9.8M+750%

Total debt$104.1M-40.4%

Total equity$218.7M+875%

Total assets$235.4M+750%

Cash flow

See full

Operating cash flow-$15.1M+16.6%

Valuation

See full

Market cap$677.17M+2,907%

Returns & leverage

See full

Return on equity-48.8%-20.0pp

Debt / equity0.9×0.0×

Current ratio18.3×+13.0×

Where this comes from

Reported directly by Relmada Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLossCarryforwards.

The official record: Relmada Therapeutics, Inc.’s 10-K, filed March 19, 2026, on SEC EDGAR. View the filing →

Ask your AI about Relmada Therapeutics, Inc.'s operating loss carryforwards.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Relmada Therapeutics, Inc.'s operating loss carryforwards?: Relmada Therapeutics, Inc. (RLMD) reported operating loss carryforwards of $4.77M in Q4 2025.
What is the long-term trend for Relmada Therapeutics, Inc.'s operating loss carryforwards?: Over 2 years (2023 to 2025), Relmada Therapeutics, Inc.'s operating loss carryforwards has grown at a -66.1% compound annual growth rate (CAGR), from $41.56M to $4.77M.